pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$FDMT4D Molecular Therapeutics, Inc.

$FDMT
Emeryville, CA, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 2: 2Phase 3: 1
2Phase 21Phase 3
Phase 3
4D-150
Wet (Neovascular / Exudative) Macular Degeneration
Phase 2
duvalgagene otiparvovec
Fabry Disease
Phase 2
plencifgene parvec
Cystic Fibrosis

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).recruitingn=514
  • phase3Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degenerationrecruitingn=480
  • phase34D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degenerationactive not recruitingn=480
  • phase24D-710 in Adult Patients With Cystic Fibrosisrecruitingn=30
  • phase24D-150 in Patients With Neovascular (Wet) Age-Related Macular Degenerationrecruitingn=215
  • phase24D-150 in Patients With Diabetic Macular Edemaactive not recruitingn=72
  • phase1Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremiaactive not recruitingn=13
  • phase24D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)active not recruitingn=21
🐶 Hiring Signal
No open roles indexed yet — view 4D Molecular Therapeutics, Inc. jobs →

News

  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 7d ago
identifiers
ticker
$FDMT
SEC CIK
0001650648
country
US
source
sec_tickers
top tags
Cystic Fibrosis1Diabetic Macular Edema1Ophthalmology1Pulmonology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 42m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?